ESR1 and breast carcinoma: Because HAS2 can be expressed by both tumor and stromal cells, tumor cell-specific gene expression levels of HAS2 were evaluated within an expanded panel of breast cancer cell lines that included ER+, HER2+ and triple negative subtypes.